GlycoMimetics (GLYC) News Today $0.33 -0.05 (-13.16%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Crescent Biopharma to Present at Jefferies London Healthcare Conference 2024November 12, 2024 | prnewswire.comGlycoMimetics and Crescent Biopharma Merger AdvancesNovember 9, 2024 | markets.businessinsider.comGlycoMimetics Announces New Uproleselan Clinical Data Will Be Presented at ASH Annual MeetingNovember 7, 2024 | finance.yahoo.comINVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. – GLYCNovember 5, 2024 | globenewswire.comINVESTIGATION ALERT: The M&A Class Action Firm Investigates the Merger of GlycoMimetics, Inc. - GLYCNovember 3, 2024 | prnewswire.comGlycoMimetics options imply 8.8% move in share price post-earningsNovember 2, 2024 | markets.businessinsider.comGLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYCNovember 1, 2024 | tmcnet.comBiotech Up Over +100% Premarket Following Merger And Funding AnnouncementOctober 31, 2024 | msn.comGlycoMimetics: NCI Phase 2/3 study of uproleselan did not meet primary endpointOctober 30, 2024 | markets.businessinsider.comGlycoMimetics Shares Are Soaring Tuesday: Here's WhyOctober 30, 2024 | msn.comGlycoMimetics Announces Merger with Crescent BiopharmaOctober 30, 2024 | finance.yahoo.comShareholder Alert: Ademi LLP Investigates Whether GlycoMimetics, Inc. is Obtaining a Fair Price for Its Public ShareholdersOctober 29, 2024 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates PFIE and GLYC on Behalf of ShareholdersOctober 29, 2024 | prnewswire.comGLYC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of GlycoMimetics, Inc. Is Fair to ShareholdersOctober 29, 2024 | businesswire.comGlycoMimetics (NASDAQ:GLYC) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comGlycoMimetics Inc (GKO.DU)September 20, 2024 | sg.finance.yahoo.comGlycoMimetics Inc (GLYC)August 31, 2024 | investing.comGlycoMimetics (GLYC) Earnings Dates & ReportsAugust 13, 2024 | investing.comGlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Public Equities L.P. Invus Sells 61,488 SharesAugust 10, 2024 | insidertrades.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Doximity (DOCS), Avinger (AVGR) and GlycoMimetics (GLYC)August 9, 2024 | markets.businessinsider.comGlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Sells $31,259.37 in StockAugust 8, 2024 | insidertrades.comGlycoMimetics, Inc. (GLYC) Stock Price, News, Quote & History - Yahoo FinanceAugust 6, 2024 | ca.finance.yahoo.comPublic Equities L.P. Invus Sells 63,564 Shares of GlycoMimetics, Inc. (NASDAQ:GLYC) StockAugust 6, 2024 | insidertrades.comInsider Selling: GlycoMimetics, Inc. (NASDAQ:GLYC) Major Shareholder Sells 258,335 Shares of StockJuly 31, 2024 | insidertrades.comTD Cowen Downgrades GlycoMimetics (GLYC)July 27, 2024 | msn.comGlycoMimetics: Strategic Overhaul and FDA Setback Justify Hold RatingJuly 26, 2024 | markets.businessinsider.comGlycoMimetics to cut workforce by about 80% in corporate restructuring planJuly 25, 2024 | msn.comGlycoMimetics Shares Drop 27% After Restructuring Plan, Job CutsJuly 25, 2024 | marketwatch.comGlycoMimetics Announces Strategic Review and Corporate Restructuring PlanJuly 25, 2024 | finance.yahoo.comGlycoMimetics, Inc. (NASDAQ:GLYC) Insider Buys $47,500.00 in StockJune 25, 2024 | insidertrades.comGlycoMimetics Announces Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)June 4, 2024 | businesswire.comGlycoMimetics to Host Key Opinion Leader Event to Review Comprehensive Results from Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) on June 4, 2024May 29, 2024 | businesswire.comPipeline Moves: Phase III AML trial fails to meet primary endpointMay 28, 2024 | finance.yahoo.comGlycoMimetics GAAP EPS of -$0.17 in-lineMay 10, 2024 | msn.comGlycoMimetics Q1 2024 Earnings PreviewMay 9, 2024 | msn.comSell Rating on Lyra Therapeutics Amid Phase 3 Study Failure and Funding ConcernsMay 8, 2024 | markets.businessinsider.comHC Wainwright & Co. Downgrades GlycoMimetics (GLYC)May 7, 2024 | msn.comGlycoMimetics' Uproleselan Flunks In Late Stage Leukemia Study, Shares SinkMay 6, 2024 | msn.comWhy Is GlycoMimetics Stock Falling In Pre-market?May 6, 2024 | markets.businessinsider.comGlycoMimetics Shares Drop After Leukemia Treatment Trial Fails to Meet Primary EndpointMay 6, 2024 | marketwatch.comGlycoMimetics Announces Results of Pivotal Phase 3 Study of Uproleselan in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)May 6, 2024 | businesswire.comWe're Keeping An Eye On GlycoMimetics' (NASDAQ:GLYC) Cash Burn RateApril 28, 2024 | finance.yahoo.comGlycoMimetics, Inc. (GLYC)April 27, 2024 | finance.yahoo.comGlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024April 25, 2024 | businesswire.comGlycoMimetics, Inc. (NASDAQ:GLYC) Sees Significant Growth in Short InterestGlycoMimetics, Inc. (NASDAQ:GLYC - Get Free Report) saw a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 1,590,000 shares, a growth of 6.7% from the March 15th total of 1,490,000 shares. Based on an average daily trading volume, of 367,100 shares, the short-interest ratio is presently 4.3 days.April 16, 2024 | marketbeat.comGlycoMimetics IncApril 15, 2024 | money.usnews.comLoss-Making GlycoMimetics, Inc. (NASDAQ:GLYC) Expected To Breakeven In The Medium-TermApril 1, 2024 | finance.yahoo.comGlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call TranscriptMarch 28, 2024 | finance.yahoo.comGlycoMimetics, Inc. Expected to Post FY2026 Earnings of $0.14 Per Share (NASDAQ:GLYC)GlycoMimetics, Inc. (NASDAQ:GLYC - Free Report) - Research analysts at HC Wainwright issued their FY2026 earnings per share (EPS) estimates for GlycoMimetics in a note issued to investors on Wednesday, March 27th. HC Wainwright analyst E. White anticipates that the biotechnology company will postMarch 28, 2024 | marketbeat.comPositive Outlook for GlycoMimetics: Buy Rating Affirmed Amid Anticipated Pivotal Trial Results and Strategic Growth InitiativesMarch 28, 2024 | markets.businessinsider.com Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump said you could learn something from this man (Ad)Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement. Here’s everything you need to know. GLYC Media Mentions By Week GLYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. GLYC News Sentiment▼0.000.45▲Average Medical News Sentiment GLYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. GLYC Articles This Week▼01▲GLYC Articles Average Week Get GlycoMimetics News Delivered to You Automatically Sign up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies bluebird bio News 23andMe News CASI Pharmaceuticals News PMV Pharmaceuticals News Ikena Oncology News Oncolytics Biotech News Quince Therapeutics News I-Mab News Clearside Biomedical News Chimerix News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:GLYC) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GlycoMimetics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GlycoMimetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
